2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000352-36-DK (EUCTR) | 27/04/2020 | 13/02/2020 | Metabolic MRI of amyotrophic lateral sclerosis and mini strokes | MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate | Amyotrophic lateral sclerosisTransient ischemic attack MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] | Product Name: Hyperpolarized [1-13C]pyruvate INN or Proposed INN: SODIUM PYRUVATE Other descriptive name: SODIUM PYRUVATE | Christoffer Laustsen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 46 | Phase 2 | Denmark |